Vasoconstriction is the narrowing of the blood vessels resulting from contraction of the muscular wall of the vessels, in particular the large arteries and small arterioles. The process is the opposite of vasodilation, the widening of blood vessels. The process is particularly important in staunching hemorrhage and acute blood loss. When blood vessels constrict, the flow of blood is restricted or decreased, thus retaining body heat or increasing vascular resistance. This makes the skin turn paler because less blood reaches the surface, reducing the radiation of heat. On a larger level, vasoconstriction is one mechanism by which the body regulates and maintains mean arterial pressure.
Medications causing vasoconstriction, also known as vasoconstrictors, are one type of medicine used to raise blood pressure. Generalized vasoconstriction usually results in an increase in systemic blood pressure, but it may also occur in specific tissues, causing a localized reduction in blood flow. The extent of vasoconstriction may be slight or severe depending on the substance or circumstance. Many vasoconstrictors also cause pupil dilation. Medications that cause vasoconstriction include: antihistamines, decongestants, and stimulants. Severe vasoconstriction may result in symptoms of intermittent claudication.
The mechanism that leads to vasoconstriction results from the increased concentration of calcium (Ca2+ ions) within vascular smooth muscle cells. However, the specific mechanisms for generating an increased intracellular concentration of calcium depends on the vasoconstrictor. Smooth muscle cells are capable of generating action potentials, but this mechanism is rarely utilized for contraction in the vasculature. Hormonal or pharmacokinetic components are more physiologically relevant. Two common stimuli for eliciting smooth muscle contraction are circulating epinephrine and activation of the sympathetic nervous system (through release of norepinephrine) that directly innervates the muscle. These compounds interact with cell surface adrenergic receptors. Such stimuli result in a signal transduction cascade that leads to increased intracellular calcium from the sarcoplasmic reticulum through IP3-mediated calcium release, as well as enhanced calcium entry across the sarcolemma through calcium channels. The rise in intracellular calcium complexes with calmodulin, which in turn activates myosin light-chain kinase. This enzyme is responsible for phosphorylating the light chain of myosin to stimulate cross-bridge cycling.
Once elevated, the intracellular calcium concentration is returned to its basal level through a variety of protein pumps and calcium exchangers located on the plasma membrane and sarcoplasmic reticulum. This reduction in calcium removes the stimulus necessary for contraction, allowing for a return to baseline.
Factors that trigger vasoconstriction can be of exogenous or endogenous origin. Ambient temperature is an example of the former. Cutaneous vasoconstriction will occur because of the body's exposure to the severe cold. Examples of endogenous factors include the autonomic nervous system, circulating hormones, and intrinsic mechanisms inherent to the vasculature itself (also referred to as the myogenic response).
Examples include amphetamines, antihistamines and cocaine. Many are used in medicine to treat hypotension and as topical decongestants. Vasoconstrictors are also used clinically to increase blood pressure or to reduce local blood flow. Vasoconstrictors mixed with local anesthetics are used to increase the duration of local anesthesia by constricting the blood vessels, thereby safely concentrating the anesthetic agent for an extended duration, as well as reducing hemorrhage.
Examples include:
|Tetrahydrozoline hydrochloride (in eye drops)|
Vasoconstriction is a procedure of the body that averts orthostatic hypotension. It is a part of a body negative feedback loop in which the body tries to restore homeostasis (maintain constant internal environment).
For example, vasoconstriction is a hypothermic preventative in which the blood vessels constrict and blood must move at a higher pressure to actively prevent a hypoxic reaction. ATP is used as a form of energy to increase this pressure to heat the body. Once homeostasis is restored, the blood pressure and ATP production regulates.
Vasoconstriction also occurs in superficial blood vessels of warm-blooded animals when their ambient environment is cold; this process diverts the flow of heated blood to the center of the animal, preventing the loss of heat.
(↑ = opens. ↓ = closes)
On vascular smooth muscle cells if not otherwise specified
(↑ = increases. ↓ = decreases)
|Stretch||↑Stretch-activated ion channels||depolarization -->|
|ATP (intracellular)||↓ATP-sensitive K+ channel|
|ATP (extracellular)||↑P2X receptor||↑Ca2+|
|NPY||NPY receptor||Activation of Gi --> ↓cAMP --> ↓PKA activity --> ↓phosphorylation of MLCK --> ↑MLCK activity --> ↑phosphorylation of MLC (calcium-independent)|
e.g., epinephrine, norepinephrine, and dopamine
|↑α1 adrenergic receptor||Activation of Gq --> ↑PLC activity --> ↑IP3 and DAG --> activation of IP3 receptor in SR --> ↑intracellular Ca2+|
|endothelin||↑endothelin receptor ETA|
|angiotensin II||↑Angiotensin receptor 1|
|open VDCCs --> ↑intracellular Ca2+|
|Asymmetric dimethylarginine||Reduced production of nitric oxide|
|Antidiuretic hormone (ADH or Vasopressin)||Arginine vasopressin receptor 1 (V1) on smooth muscle cells||Activation of Gq --> ↑PLC activity --> ↑IP3 and DAG --> activation of IP3 receptor in SR --> ↑intracellular Ca2+|
|Arginine vasopressin receptor on endothelium||Endothelin production|
|Various receptors on endothelium||Endothelin production|
Improper vasoconstriction may also play a role in secondary hypertension.
- Addison's disease
- Nitric oxide
- Postural orthostatic tachycardia syndrome
- "Medihaler Ergotamine". drugs.com. Retrieved 2016-05-20.
- Michael P. Walsh; et all (August 2005). "Thromboxane A2-induced contraction of rat caudal arterial smooth muscle involves activation of Ca2+ entry and Ca2+sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855 but not Thr-697" (PDF). Biochem. J. 389 (Pt 3): 763–74. doi:10.1042/BJ20050237. PMC . PMID 15823093. Archived from the original (PDF) on 2011-07-13. Retrieved 2009-07-20.
- Yagiela JA (1995). "Vasoconstrictor agents for local anesthesia". Anesth Prog. 42 (3–4): 116–20. PMC . PMID 8934977.
- Unless else specified in box, then ref is: Walter F. Boron. Medical Physiology: A Cellular And Molecular Approaoch. Elsevier/Saunders. ISBN 1-4160-2328-3. Page 479
- Rod Flower; Humphrey P. Rang; Maureen M. Dale; Ritter, James M. (2007). Rang & Dale's pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-06911-5.
- Walter F. Boron. Medical Physiology: A Cellular And Molecular Approach. Elsevier/Saunders. ISBN 1-4160-2328-3. Page 771
- Richard Milsten and Julian Slowinski, The sexual male, bc, main point W.W. Norton Company, New York, London (1999) ISBN 0-393-04740-7
|Wikimedia Commons has media related to Vasoconstrictors.|